TLR2 Agonist Immunostimulation for Broad Innate Protection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current vaccines against influenza A virus (IAV) are ineffective against pandemic outbreaks and require annual reformulation, and existing treatments lack broad protection against influenza and other infectious diseases and cancers.

Innovation Solution

Administering a TLR2 moiety comprising a TLR2 agonist, such as Pam2Cys, to elicit an innate immune response in a subject without inducing a specific humoral or cellular immune response against the TLR2 moiety, thereby providing prophylactic and therapeutic effects against infections and cancers.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional vaccines targeting surface proteins (neuraminidase and hemagglutinin) are used, then antibodies are induced against these proteins, but the vaccines require annual re-formulation and are ineffective against pandemic outbreaks

Engineering Contradiction:

Improvevaccine effectivenessVSAvoidbroad protection against different influenza strains

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention extracts and targets the conserved internal regions of influenza viruses (such as nucleoprotein and matrix protein) rather than the variable surface proteins. This extraction of the core conserved antigens allows the vaccine to induce immunity against multiple influenza strains without requiring annual reformulation, resolving the contradiction between reliability and adaptability

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The vaccine composition is designed to provide universal protection against multiple influenza A and B strains by targeting conserved internal regions that are common across different viral subtypes. This multi-functional approach enables a single vaccine formulation to protect against various influenza strains, eliminating the need for annual re-formulation while maintaining effectiveness

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If vaccines are reformulated annually to match evolving surface proteins, then protection against seasonal epidemics is maintained, but the complexity of vaccine development and administration increases

Engineering Contradiction:

Improveprotection against seasonal influenzaVSAvoidvaccine re-formulation and administration process

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The invention takes preliminary action by targeting the conserved internal regions of influenza viruses that remain relatively stable over time. By focusing on these invariant antigens, the vaccine provides preliminary and lasting protection that does not require annual re-formulation, thereby reducing the complexity of the vaccination program while maintaining reliable protection

Inventive Principle:

Principle #10Preliminary action

3Adaptability or versatility

If treatments target specific antigens of influenza virus, then immune response is directed against those antigens, but broad protection against influenza and other infectious diseases is limited

Engineering Contradiction:

Improvespecific immune responseVSAvoidbroad protection against infections and cancers

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The vaccine composition provides universal immunity by targeting conserved internal regions of influenza viruses that are common across different strains and types. This approach enables a single vaccine to protect against multiple influenza A and B strains, as well as providing cross-protection against other respiratory pathogens, thereby expanding adaptability while maintaining reliable broad protection

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The invention uses an adjuvant system comprising Toll-like receptor agonists as intermediaries to enhance and broaden the immune response. These adjuvants act as mediators that stimulate innate immunity and enhance adaptive immune responses against the conserved influenza antigens, thereby extending protection to include other infectious diseases and even showing anti-cancer activity

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The TLR2 agonist triggers a non-antigen-specific innate immune response, significantly reducing viral loads and morbidity in influenza infections and providing immediate protection against various pathogens, including influenza A and bacteria like L. pneumophila, and inhibiting cancer growth.

Implementation Method 1

a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist

Methodology Applied

Scientific EffectToll-like receptor recognition:

Data Source

PatentUS12569431B2Immunostimulatory method

Publication Date: 2026.03.10 ENA RESPIRATORY PTY LTD

AI summary

This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.